Results 21 to 30 of about 28,303 (260)
Journal of Diabetes Investigation, 2020 Japan's guidelines emphasize tailored therapy, but do not guide physicians on the use of a specific regimen in drug‐naive patients. The role of long‐term initial therapy could be important in key elements of diabetes treatment, such as continuation of ...
Takeshi Horii +3 more
doaj +1 more source
Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
Frontiers in Endocrinology, 2021 Vascular aging is characterized by alterations in the constitutive properties and biological functions of the blood vessel wall. Endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) are indispensability elements in the inner layer and the ...
Fen Cao +3 more
doaj +1 more source
Journal of Diabetes Investigation, 2020 Aims/Introduction To explore the factors associated with the glucose‐lowering efficacy of sitagliptin treatment in Japanese patients with type 2 diabetes mellitus.
Naoko Tajima +5 more
doaj +1 more source
Systematic review of clinical and economic effectiveness of vildagliptin in type 2 diabetic patients with poor glycemic control on monotherapy with metformin [PDF]
Ķazaķstannyṇ Klinikalyķ Medicinasy, 2018 Aim: A study was conducted to assess the clinical and economic effectiveness of vildagliptin in adults with type 2 diabetes mellitus (T2DM) with poor glycemic control against the metformin monotherapy.
Alima Almadiyeva +3 more
doaj +1 more source
Journal of Clinical Medicine, 2022 Dipeptidyl peptidase 4 (DPP-4) is a novel adipokine and may be involved in the association between adipose tissue and metabolic syndrome. We investigated DPP-4 and adiponectin levels in the serum, subcutaneous adipose tissue (SAT), and epicardial adipose tissue (EAT), and their relationship with preoperative factors, as well as comparing the DPP-4 ...
Ikuko Shibasaki +15 more
openaire +2 more sources
The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease
Frontiers in Immunology, 2015 Despite major advances in the understanding of the molecular mechanisms that underpin the development of diabetic kidney disease, current best practice still leaves a significant proportion of patients with end stage kidney disease requiring renal ...
Usha ePanchapakesan, Carol ePollock
doaj +1 more source
Journal of Diabetes Investigation, 2022 Aims/Introduction The union of dipeptidyl peptidase‐4 inhibitors and insulin in patients with type 2 diabetes and chronic kidney disease provides satisfactory glucose management without increasing adverse events (AEs).
Xianling Zhou +4 more
doaj +1 more source
Acta Pharmaceutica Sinica B, 2014 Dipeptidyl peptidase 4 (DPP4) is recognised as an attractive anti-diabetic drug target, and several DPP4 inhibitors are already on the market. As members of the same gene family, dipeptidyl peptidase 8 (DPP8) and dipeptidyl peptidase 9 (DPP9) share high ...
Jinglong Liu +4 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Background Randomized controlled trials showed that newer glucose‐lowering agents are cardioprotective, but most participants were men. It is unknown whether benefits are similar in women.
Valeria Raparelli +6 more
doaj +1 more source
Dipeptidyl peptidase-4 inhibitor-related renal disease
Journal of Diabetes and its Complications, 2023 Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used to treat type 2 diabetes (T2D). Lowering blood glucose is expected also to reduce the progression of diabetic nephropathy. We experienced a patient with T2D who achieved good glycemic control with a DPP-4 inhibitor but experienced rapid deterioration of renal function.
Atsuhiko, Suenaga +16 more
openaire +2 more sources